Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

-current portion of equipment

financing 1,352,684 955,695

Deferred rent and other non-current

liabilities 1,576,734 1,464,902

Total liabilities 11,851,683 12,472,671

Commitments

Stockholders' equity:

Common stock 3,437 2,944

Additional paid-in capital 320,579,240 298,073,896

Deferred stock-based compensation (251,601) (1,006,604)

Accumulated other comprehensive

income (loss) 69,262 (21,376)

Accumulated deficit (279,006,083) (240,245,163)

Total stockholders' equity 41,394,255 56,803,697

Total liabilities and stockholders'

equity $53,245,938 $69,276,368

Note 1: The condensed balance sheet at December 31, 2006 has been

derived from the audited financial statements at that date

included in the Company's Form 10-K for the fiscal year ended

December 31, 2006.

SUNESIS PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Three months ended Twelve months ended

December 31, December 31,

2007 2006 2007 2006

Revenue:

Collaboration

revenue $37,500 $229,167 $1,576,610 $6,353,585

Collaboration

revenue from

related party 1,759,208 1,725,810 7,586,903 7,317,700

License revenue 250,000 - 500,000 -

Grant and

fellowship

revenue
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... - When it comes to innovation, American Family Insurance's ... , Chapman The direction comes from within, and ... it up with a familiar phrase: nothing ventured, nothing gained. ... established a venture program modeled after employee-driven, quality-control programs. ...
... help parts of Wisconsin that aren't destined to become the ... dollars in medical research grants? For an answer, let's take ... suburban Madison. , ,Imago is a shining example of Wisconsin's ... chemical, electrical, and optical secrets of molecules and atoms. A ...
... case "i" next to a word as a way to create ... may be possible, the chances of creating a long-lasting, global iconic ... exclusive longevity of its unique name, and for that reason you ... and not iTV. , ,Terms like interactive and portable were ...
Cached Biology Technology:CIO Leadership Series: Byrne Chapman, American Family Insurance 2CIO Leadership Series: Byrne Chapman, American Family Insurance 3CIO Leadership Series: Byrne Chapman, American Family Insurance 4How a healthy tech-based economy helps others in Wisconsin 2How a healthy tech-based economy helps others in Wisconsin 3How a healthy tech-based economy helps others in Wisconsin 4The I of the storm: iPhones, iPains, and iProblems 2The I of the storm: iPhones, iPains, and iProblems 3The I of the storm: iPhones, iPains, and iProblems 4
(Date:1/22/2015)... , Europe,s most prestigious innovation prize ... present a video retrospective of the most exciting and innovative nominations  ... and Sophie Wilson   A different theme ... Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its new ... G2 model. The G2 sets a higher standard for collecting ... capital management solution. With plug-and-play installation, touch screen interface and ... provides a robust time collection solution for the small to ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2The Global Watermarking and Fingerprinting Markets 2
... leading expert in light-emitting diodes, is intensifying the properties ... Electrons move constantly think of tiny particles ... is through the movement of these electrons that electric ... Eminent Scholar Andrew Steckl is one of the world,s ...
... Neanderthals died out because of competition with modern ... scientists have gained increased knowledge of past climate ... character at the time of the Neanderthal disappearance. ... researchers, published this week in the prestigious journal ...
... 10, 2007) -- It,s well known that smoking cigarettes ... from cancer to heart disease. Now a new study ... looks at how they do their dirty work by ... evidence points to nicotine, the addictive chemical in cigarettes. ...
Cached Biology News:Salmon garnish points the way to green electronics 2Salmon garnish points the way to green electronics 3Climate -- no smoking gun for Neanderthals 2Nicotine may accelerate atherosclerosis, may be as dangerous as tar 2Nicotine may accelerate atherosclerosis, may be as dangerous as tar 3
Insect Cell Lysis Buffer 50 ml...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
AK6 Antibody...
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
Biology Products: